Literature DB >> 2149841

Atrial natriuretic peptide in primary pulmonary hypertension.

A H Morice1, J Pepke-Zaba, M J Brown, P S Thomas, T W Higenbottam.   

Abstract

Plasma levels of atrial natriuretic peptide (ANP) were determined during cardiac catheterization in nine patients with primary pulmonary hypertension (PPH) and the effect of prostacyclin infusion via a right heart catheter studied. The role of hypoxia on the release of ANP was investigated in a control group of six normal subjects who underwent an acute hypoxic challenge. Patients showed the typical haemodynamic changes of primary pulmonary hypertension with elevation of mean (SD) pulmonary artery pressure, 71.3 (13.8) mmHg, and low cardiac index, 1.9 (0.5) l.min-1.m-2. Plasma ANP was also elevated; mean pulmonary artery plasma ANP was 96.3 (77.6) pmol.l-1 in PPH patients compared with mean venous plasma ANP of 8.9 (5.6) pmol.l-1 in normal subjects. Prostacyclin infusion in PPH patients and hypoxic challenge in normal subjects did not significantly alter plasma ANP levels. The elevated levels of ANP in PPH are due to the altered haemodynamics secondary to increased pulmonary vascular resistance and may be responsible for the lack of peripheral oedema seen in this condition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149841

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

1.  Urinary cGMP concentrations in severe primary pulmonary hypertension.

Authors:  M Bogdan; M Humbert; J Francoual; C Claise; P Duroux; G Simonneau; A Lindenbaum
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Treatment-related biomarkers in pulmonary hypertension.

Authors:  Aparna C Swaminathan; Alex C Dusek; Tim J McMahon
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

3.  Effects of atrial natriuretic peptide and nitroprusside on isolated pulmonary resistance and conduit arteries from rats with pulmonary hypertension.

Authors:  J C Wanstall; J S Thompson; A H Morice
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

4.  Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.

Authors:  T K Rogers; W Sheedy; J Waterhouse; P Howard; A H Morice
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

5.  Neural control of the endocrine rat heart.

Authors:  J H Jiao; A J Baertschi
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

Review 6.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

7.  Exercise increases the release of atrial natriuretic peptide in heart transplant recipients.

Authors:  J Pepke-Zaba; T W Higenbottam; A Morice; A T Dinh-Xuan; A E Raine; J Wallwork
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.

Authors:  A H Cohen; K Hanson; K Morris; B Fouty; I F McMurty; W Clarke; D M Rodman
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia.

Authors:  J S Thompson; W Sheedy; A H Morice
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

10.  Changes in atrial natriuretic peptide concentrations during intravenous saline infusion in hypoxic cor pulmonale.

Authors:  A G Stewart; P A Bardsley; S V Baudouin; J C Waterhouse; J S Thompson; A H Morice; P Howard
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.